NCT05260073View on ClinicalTrials.gov

Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis

CompletedOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

October 31, 2022

Study Completion Date

March 7, 2023

Conditions

Keratosis, Actinic

Interventions

DRUG

Tirbanibulin

Participants will be treated with tirbanibulin ointment 1% (2.5 mg tirbanibulin in 250 mg) as 1 single-dose packet per application, for 5 consecutive days.

Trial Locations (1)

29401

Almirall Investigational Site 1, Charleston